Novartis halts early trial of targeted radiation drug for tough cancers
NCT ID NCT05977322
Summary
This was an early-stage study to test the safety and find the right dose of a new radioactive drug called 177Lu-FF58 for people with advanced pancreatic, stomach, or brain cancer. The drug is designed to deliver radiation directly to tumors. The study was terminated early, and its main goal was to understand side effects and how the drug behaves in the body, not to prove it cures cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Nijmegen, 6500HB, Netherlands
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, 08907, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Geneva, CH 1211, Switzerland
Conditions
Explore the condition pages connected to this study.